Trial Outcomes & Findings for Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease (NCT NCT00511329)
NCT ID: NCT00511329
Last Updated: 2018-04-12
Results Overview
TERMINATED
PHASE2/PHASE3
10 participants
12 months
2018-04-12
Participant Flow
PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Participant milestones
| Measure |
Somatropin
somatropin \[rDNA origin\] for injection: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 12 monthsPopulation: PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 12 monthsPopulation: PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.
Outcome measures
Outcome data not reported
Adverse Events
Somatropin
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place